Tenderwize
Back to tender search

Non-exclusive discount agreement for sodium oxybate

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Nov 30, 2027 · 418 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Natriumoxybat (ATC-Code nach WHO: N07XX04)

20/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

20 / 100

Complexity

20 / 100

Risk factors

No guaranteed quantities; actual revenue depends on unknown prescription volumes.

The contracting authority may terminate the Open-House process early if exclusive discount agreements are concluded.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Nov 30, 2027

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Nov 2027
  • Conclusion of non-exclusive discount agreements for sodium oxybate (ATC N07XX04)
  • Open-House model: any qualifying pharmaceutical entrepreneur can participate
Show full summary

This tender is a non-exclusive discount agreement (Rabattvereinbarung) under § 130a Abs. 8 SGB V for the active substance sodium oxybate (ATC N07XX04) using an Open-House model. The contracting authority is AOK PLUS for the states of Saxony and Thuringia. Participation is open to all interested pharmaceutical entrepreneurs meeting eligibility criteria. No individual negotiations, no exclusivity, and no guaranteed purchase volumes. The framework ends on 30.11.2027. Submissions are electronic via DTVP portal. First submission deadline is 04.11.2025, with further rolling deadlines.

Risks

No guaranteed quantities; actual revenue depends on unknown prescription volumes.

The contracting authority may terminate the Open-House process early if exclusive discount agreements are concluded.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Participant must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG

Eligibility

  • Must submit self-declaration on absence of grounds for exclusion (according to §§ 123, 124 GWB)

Administrative

  • Must submit self-declaration on compliance with Russia sanctions (EU Regulation 833/2014)

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria specified; the procedure is based on acceptance of predefined terms.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive discount agreement for sodium oxybate

Non-exclusive discount agreement for pharmaceutical products containing sodium oxybate, under an Open-House model. No exclusivity, no minimum volumes, and no individual negotiations.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Nov 2025 - Nov 2027

Category

Pharmaceutical products

Award Criteria

No award criteria specified; the procedure is based on acceptance of predefined terms.

Deadline

Deadline Nov 30, 2027

Procurement Details

Publication date
17 Sep 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
609690-2025

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30